Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.051
Neutral
RSI(14)
35.697
Neutral
STOCH(KDJ)(9,3,3)
17.392
Sell
ATR(14)
1.259
High Vlolatility
CCI(14)
-133.737
Sell
Williams %R
97.273
Oversold
TRIX(12,20)
-0.300
Sell
StochRSI(14)
0.000
Sell
Search
Maze Therapeutics Inc
MAZEAdd to Watchlist
23.790USD
+0.210+0.89%
Market hours （ET）Quotes delayed by 15 min
1.18BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Maze Therapeutics Inc
Currency: USD Updated: 2026-06-08Key Insights
Maze Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 390 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 63.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Maze Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Maze Therapeutics Inc Highlights
StrengthsRisks
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -10.01, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 53.41M shares, increasing 18.83% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 169.00 shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
63.500
Target Price
+161.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-06-08The current financial score of Maze Therapeutics Inc is 8.48, ranking 42 out of 390 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.
Score
Financials
8.64
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.50
Operational Efficiency
10.00
Growth Potential
7.93
Shareholder Returns
7.35
Maze Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-06-08The current valuation score of Maze Therapeutics Inc is 6.70, ranking 225 out of 390 in the Biotechnology & Medical Research industry. Its current P/E ratio is -10.01, which is -2147.97% below the recent high of 205.07 and -102.32% above the recent low of -20.26.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 26/390
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-06-08The current earnings forecast score of Maze Therapeutics Inc is 8.83, ranking 49 out of 390 in the Biotechnology & Medical Research industry. The average price target is 39.50, with a high of 60.00 and a low of 34.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
63.500
Target Price
+169.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
558
Total
5
Median
6
Average
Company name
Ratings
Analysts
Maze Therapeutics Inc
MAZE
12
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-06-08The current price momentum score of Maze Therapeutics Inc is 6.36, ranking 254 out of 390 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 25.98 and the support level at 22.34, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
24.480
Sell
MA10
25.312
Sell
MA20
25.445
Sell
MA50
26.539
Sell
MA100
36.118
Sell
MA200
33.394
Sell
Institutional Confidence
Currency: USD Updated: 2026-06-08Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-06-08The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Maze Therapeutics Inc is 5.31, ranking 45 out of 390 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+54.51%
240-Day Volatility
+90.51%
Return
Best Daily Return
60 days
+4.58%
120 days
+13.30%
5 years
--
Worst Daily Return
60 days
-35.24%
120 days
-35.24%
5 years
--
Sharpe Ratio
60 days
-3.31
120 days
-1.07
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+54.51%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
+2.35
3 years
--
5 years
--
Skewness
240 days
+3.00
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+90.51%
5 years
--
Standardised True Range
240 days
+9.04%
5 years
--
Downside Risk-Adjusted Return
120 days
-111.44%
240 days
-111.44%
Maximum Daily Upside Volatility
60 days
+57.03%
Maximum Daily Downside Volatility
60 days
+81.38%
Liquidity
Average Turnover Rate
60 days
+2.00%
120 days
+1.53%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Maze Therapeutics Inc
MAZE
7.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Veracyte Inc
VCYT
8.29 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
